NFL Biosciences SA

NEW
XPAR:ALNFL (France)  
€ 2.02 (-2.88%) Oct 30
At Loss
P/B:
8.74
Market Cap:
€ 19.42M ($ 21.12M)
Enterprise V:
€ 15.73M ($ 17.11M)
Volume:
7.22K
Avg Vol (2M):
34.04K
Trade In:
Volume:
7.22K
At Loss
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for NFL Biosciences SA ( ) from 2021 to Oct 31 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. NFL Biosciences stock (XPAR:ALNFL) PE ratio as of Oct 31 2024 is 0. More Details

NFL Biosciences SA (XPAR:ALNFL) PE Ratio (TTM) Chart

To

NFL Biosciences SA (XPAR:ALNFL) PE Ratio (TTM) Historical Data

Total 600
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
NFL Biosciences PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-10-31 At Loss 2024-08-29 At Loss
2024-10-30 At Loss 2024-08-28 At Loss
2024-10-29 At Loss 2024-08-27 At Loss
2024-10-28 At Loss 2024-08-26 At Loss
2024-10-25 At Loss 2024-08-23 At Loss
2024-10-24 At Loss 2024-08-22 At Loss
2024-10-23 At Loss 2024-08-21 At Loss
2024-10-22 At Loss 2024-08-20 At Loss
2024-10-21 At Loss 2024-08-19 At Loss
2024-10-18 At Loss 2024-08-16 At Loss
2024-10-17 At Loss 2024-08-15 At Loss
2024-10-16 At Loss 2024-08-14 At Loss
2024-10-15 At Loss 2024-08-13 At Loss
2024-10-14 At Loss 2024-08-12 At Loss
2024-10-11 At Loss 2024-08-09 At Loss
2024-10-10 At Loss 2024-08-08 At Loss
2024-10-09 At Loss 2024-08-07 At Loss
2024-10-08 At Loss 2024-08-06 At Loss
2024-10-07 At Loss 2024-08-05 At Loss
2024-10-04 At Loss 2024-08-02 At Loss
2024-10-03 At Loss 2024-08-01 At Loss
2024-10-02 At Loss 2024-07-31 At Loss
2024-10-01 At Loss 2024-07-30 At Loss
2024-09-30 At Loss 2024-07-29 At Loss
2024-09-27 At Loss 2024-07-26 At Loss
2024-09-26 At Loss 2024-07-25 At Loss
2024-09-25 At Loss 2024-07-24 At Loss
2024-09-24 At Loss 2024-07-23 At Loss
2024-09-23 At Loss 2024-07-22 At Loss
2024-09-20 At Loss 2024-07-19 At Loss
2024-09-19 At Loss 2024-07-18 At Loss
2024-09-18 At Loss 2024-07-17 At Loss
2024-09-17 At Loss 2024-07-16 At Loss
2024-09-16 At Loss 2024-07-15 At Loss
2024-09-13 At Loss 2024-07-12 At Loss
2024-09-12 At Loss 2024-07-11 At Loss
2024-09-11 At Loss 2024-07-10 At Loss
2024-09-10 At Loss 2024-07-09 At Loss
2024-09-09 At Loss 2024-07-08 At Loss
2024-09-06 At Loss 2024-07-05 At Loss
2024-09-05 At Loss 2024-07-04 At Loss
2024-09-04 At Loss 2024-07-03 At Loss
2024-09-03 At Loss 2024-07-02 At Loss
2024-09-02 At Loss 2024-07-01 At Loss
2024-08-30 At Loss 2024-06-28 At Loss

NFL Biosciences SA (XPAR:ALNFL) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.